Rezatapopt free base · Synonyms: PC14586 | PC-14586

Rezatapopt (PC14586) is an antineoplastic agent, used to inhibit solid tumor with p53 mutation.

For research use only. Not for human or veterinary use.

Target MDM-2/p53

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS

Rezatapopt structure

CAS No.: 2636846-41-6

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
25 mg	USD 485.00	BP-02038-25mg	In stock	Get quote
50 mg	USD 850.00	BP-02038-50mg	In stock	Get quote
100 mg	USD 1,450.00	BP-02038-100mg	Inquire	Get quote
250 mg	USD 2,850.00	BP-02038-250mg	In stock	Get quote
500 mg	USD 4,500.00	BP-02038-500mg	In stock	Get quote

Need another size or custom synthesis? Request a quote.

Description

Rezatapopt (PC14586) is an antineoplastic agent, used to inhibit solid tumor with p53 mutation.

Biological activity

In Vivo Rezatapopt induces complete regression of tumors in mice and potentiated checkpoint therapy.

Identifiers

SMILES: FC(F)(F)CN1C2=CC=CC(N[C@H]3[C@H](CN(CC3)C)F)=C2C=C1C#CCNC4=C(C=C(C=C4)C(NC)=O)OC
InChIKey: NKRKBSQLUPEVCZ-JTHBVZDNSA-N

Specifications

MW (average): 545.5717
Formula: C₂₈H₃₁F₄N₅O₂
CAS No.: 2636846-41-6
Physical state: Solid
Color: Off-white to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: 4°C, protect from light

Solubility

Soluble in DMSO : 50 mg/mL

Documents

References

[1]. Li Sujing, et al. Heteroarylalkyne compounds for targeting mutant of p53 and their preparation. World Intellectual Property Organization, WO2023016434 A1. 2023-02-16.

[2]. Vu BT, et al. Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development. ACS Med Chem Lett. 2024 Nov 4;16(1):34-39.

[3]. Spiegelberg D, et al. Targeting mutant p53: Evaluation of novel anti-p53R175H monoclonal antibodies as diagnostic tools. Sci Rep. 2025 Jan 6;15(1):1000.

[4]. Schram A M, et al. 691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation[J]. Annals of oncology, 2024, 35: S535-S536.

Same target

Search MDM-2/p53

Same research area

Search Cancer